Pharvaris (PHVS) Stock Highlights

16.49 | -0.06%

2025-02-22 05:06:13

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Statistics

Range Today

16.06 17.01

Volume Today 59.1K

Range 1 Year

15.21 28.84

Volume 1 Year 18.95M

Range 3 Year

1.77 33

Volume 3 Year 156.16M

Range 10 Year

1.77 42.86

Volume 10 Year 169.62M

Highlights

Market Capitalization 894.3M (small)

Floating Shares 19.15M

Current Price 16.49

Price To Earnings -6.07

Price To Book 3.01

Earnings Per Share -2.72

Payout Ratio 0%

Performance

Latest -0.06%

1 Month -9.84%

3 Months -20.38%

6 Months -8.18%

1 Year -40.3%

3 Years -4.13%

5 Years -34.04%

10 Years -34.04%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.